1. Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile.
Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. The typical patient was defined as a female, aged 57 years, with a body mass index of 30 kg/m2, and a baseline CDAI of 20, who had received 1 prior biological agent and had no comorbidities other than rheumatoid arthritis on the modified Charlson comorbidity index. Anti-CCP status was defined as either anti-CCP–positive (≥ 20 units/ml) or anti-CCP–negative (< 20 units/ml). Patient numbers: abatacept anti-CCP+, n = 361; abatacept anti-CCP−, n = 203; TNF anti-CCP+, n = 1110; TNF anti-CCP−, n = 600. Anti-CCP: anticyclic citrullinated peptide antibodies; CDAI: Clinical Disease Activity Index; TNFi: tumor necrosis factor-α inhibitor.
Leslie R. Harrold et al. J Rheumatol 2018;45:32-39
©2018 by The Journal of Rheumatology